Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury

M. Arditi, J. Zhou, He Huang Sheng He Huang, P. M. Luckett, M. N. Marra, Sik Kim Kwang Sik Kim

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Bactericidal/permeability-increasing protein (BPI), a human neutrophil granule protein, has been shown to bind lipopolysaccharide (LPS) and neutralize LPS-mediated cytokine production in adherent monocytes and the whole-blood system. In this study we investigated the ability of recombinant human BPI (rBPI) to inhibit LPS-induced vascular endothelial cell (EC) injury and activation. rBPI inhibited significantly both rough and smooth LPS- mediated injury for cultured bovine brain microvessel ECs, as measured by lactic dehydrogenase release, and blocked the LPS-induced interleukin-6 (IL- 6) release from human umbilical vein ECs in a dose-dependent manner. BPI was able to inhibit LPS-mediated EC injury or activation whether it was added before or at the same time with LPS, but delaying the time of addition of rBPI resulted only in a partial inhibition. BPI also inhibited LPS-induced tumor necrosis factor alpha, IL-1β, and IL-6 release from human whole blood. This inhibition of tumor necrosis factor alpha, IL-1β, and IL-6 release from whole blood was maximal when BPI was premixed with LPS before addition to blood and was partial when BPI was added simultaneously with LPS, but no inhibition was observed when the addition of rBPI was delayed for 5 min. These findings suggest that rBPI is a potent inhibitor of LPS-mediated responses in ECs and whole blood and underscore the potential use of BPI in treatment or prevention of endotoxic shock. In contrast, the anti-lipid A monoclonal antibodies HA-1A and E5 were ineffective in inhibiting LPS- mediated EC injury and activation as well as LPS-induced cytokine release in whole blood.

Original languageEnglish (US)
Pages (from-to)3930-3936
Number of pages7
JournalInfection and Immunity
Volume62
Issue number9
StatePublished - 1994

Fingerprint

Lipopolysaccharides
Endothelial Cells
Wounds and Injuries
Interleukin-6
Interleukin-1
bactericidal permeability increasing protein
Tumor Necrosis Factor-alpha
Cytokines
Lipid A
Umbilical Veins
Septic Shock
Microvessels
Monocytes
Oxidoreductases
Milk
Neutrophils

ASJC Scopus subject areas

  • Immunology

Cite this

Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. / Arditi, M.; Zhou, J.; Sheng He Huang, He Huang; Luckett, P. M.; Marra, M. N.; Kwang Sik Kim, Sik Kim.

In: Infection and Immunity, Vol. 62, No. 9, 1994, p. 3930-3936.

Research output: Contribution to journalArticle

Arditi, M. ; Zhou, J. ; Sheng He Huang, He Huang ; Luckett, P. M. ; Marra, M. N. ; Kwang Sik Kim, Sik Kim. / Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. In: Infection and Immunity. 1994 ; Vol. 62, No. 9. pp. 3930-3936.
@article{c78401555dd14e449888429dd6c210c4,
title = "Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury",
abstract = "Bactericidal/permeability-increasing protein (BPI), a human neutrophil granule protein, has been shown to bind lipopolysaccharide (LPS) and neutralize LPS-mediated cytokine production in adherent monocytes and the whole-blood system. In this study we investigated the ability of recombinant human BPI (rBPI) to inhibit LPS-induced vascular endothelial cell (EC) injury and activation. rBPI inhibited significantly both rough and smooth LPS- mediated injury for cultured bovine brain microvessel ECs, as measured by lactic dehydrogenase release, and blocked the LPS-induced interleukin-6 (IL- 6) release from human umbilical vein ECs in a dose-dependent manner. BPI was able to inhibit LPS-mediated EC injury or activation whether it was added before or at the same time with LPS, but delaying the time of addition of rBPI resulted only in a partial inhibition. BPI also inhibited LPS-induced tumor necrosis factor alpha, IL-1β, and IL-6 release from human whole blood. This inhibition of tumor necrosis factor alpha, IL-1β, and IL-6 release from whole blood was maximal when BPI was premixed with LPS before addition to blood and was partial when BPI was added simultaneously with LPS, but no inhibition was observed when the addition of rBPI was delayed for 5 min. These findings suggest that rBPI is a potent inhibitor of LPS-mediated responses in ECs and whole blood and underscore the potential use of BPI in treatment or prevention of endotoxic shock. In contrast, the anti-lipid A monoclonal antibodies HA-1A and E5 were ineffective in inhibiting LPS- mediated EC injury and activation as well as LPS-induced cytokine release in whole blood.",
author = "M. Arditi and J. Zhou and {Sheng He Huang}, {He Huang} and Luckett, {P. M.} and Marra, {M. N.} and {Kwang Sik Kim}, {Sik Kim}",
year = "1994",
language = "English (US)",
volume = "62",
pages = "3930--3936",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury

AU - Arditi, M.

AU - Zhou, J.

AU - Sheng He Huang, He Huang

AU - Luckett, P. M.

AU - Marra, M. N.

AU - Kwang Sik Kim, Sik Kim

PY - 1994

Y1 - 1994

N2 - Bactericidal/permeability-increasing protein (BPI), a human neutrophil granule protein, has been shown to bind lipopolysaccharide (LPS) and neutralize LPS-mediated cytokine production in adherent monocytes and the whole-blood system. In this study we investigated the ability of recombinant human BPI (rBPI) to inhibit LPS-induced vascular endothelial cell (EC) injury and activation. rBPI inhibited significantly both rough and smooth LPS- mediated injury for cultured bovine brain microvessel ECs, as measured by lactic dehydrogenase release, and blocked the LPS-induced interleukin-6 (IL- 6) release from human umbilical vein ECs in a dose-dependent manner. BPI was able to inhibit LPS-mediated EC injury or activation whether it was added before or at the same time with LPS, but delaying the time of addition of rBPI resulted only in a partial inhibition. BPI also inhibited LPS-induced tumor necrosis factor alpha, IL-1β, and IL-6 release from human whole blood. This inhibition of tumor necrosis factor alpha, IL-1β, and IL-6 release from whole blood was maximal when BPI was premixed with LPS before addition to blood and was partial when BPI was added simultaneously with LPS, but no inhibition was observed when the addition of rBPI was delayed for 5 min. These findings suggest that rBPI is a potent inhibitor of LPS-mediated responses in ECs and whole blood and underscore the potential use of BPI in treatment or prevention of endotoxic shock. In contrast, the anti-lipid A monoclonal antibodies HA-1A and E5 were ineffective in inhibiting LPS- mediated EC injury and activation as well as LPS-induced cytokine release in whole blood.

AB - Bactericidal/permeability-increasing protein (BPI), a human neutrophil granule protein, has been shown to bind lipopolysaccharide (LPS) and neutralize LPS-mediated cytokine production in adherent monocytes and the whole-blood system. In this study we investigated the ability of recombinant human BPI (rBPI) to inhibit LPS-induced vascular endothelial cell (EC) injury and activation. rBPI inhibited significantly both rough and smooth LPS- mediated injury for cultured bovine brain microvessel ECs, as measured by lactic dehydrogenase release, and blocked the LPS-induced interleukin-6 (IL- 6) release from human umbilical vein ECs in a dose-dependent manner. BPI was able to inhibit LPS-mediated EC injury or activation whether it was added before or at the same time with LPS, but delaying the time of addition of rBPI resulted only in a partial inhibition. BPI also inhibited LPS-induced tumor necrosis factor alpha, IL-1β, and IL-6 release from human whole blood. This inhibition of tumor necrosis factor alpha, IL-1β, and IL-6 release from whole blood was maximal when BPI was premixed with LPS before addition to blood and was partial when BPI was added simultaneously with LPS, but no inhibition was observed when the addition of rBPI was delayed for 5 min. These findings suggest that rBPI is a potent inhibitor of LPS-mediated responses in ECs and whole blood and underscore the potential use of BPI in treatment or prevention of endotoxic shock. In contrast, the anti-lipid A monoclonal antibodies HA-1A and E5 were ineffective in inhibiting LPS- mediated EC injury and activation as well as LPS-induced cytokine release in whole blood.

UR - http://www.scopus.com/inward/record.url?scp=0028065107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028065107&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 3930

EP - 3936

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 9

ER -